Factor Xa inhibition in interventional cardiology;Faktor-Xa-Inhibition in der interventionellen Kardiologie

Hamostaseologie

Volumn 27, Issue 5, 2007, Pages 328-332

  Ahrens, I ^a,b   Peter, K ^b   Bode, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Acute coronary syndrome; DX 9065a; Factor xa; Fondaparinux; Idraparinux; Otamixaban; Pci

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A;

ACUTE CORONARY SYNDROME; ARTICLE; DRUG ANTAGONISM; HUMAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; ANTITHROMBIN III; FACTOR XA; HUMANS;

EID: 38749093392     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616998     Document Type: Article

References (68)

1. Weiss HJ. Platelet physiology and abnormalities of platelet function (first of two parts). N Engl J Med 1975, 293, 531-541.
2. Baumgartner HR. Platelet interaction with collagen fibrils in flowing blood. I. Reaction of human platelets with alpha chymotrypsin-digested subendothelium. Thromb Haemost 1977, 37, 1-16.
3. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002, 8, 1227-1234.
4. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996, 84, 289-297.
5. Nieswandt B, Brakebusch C, Bergmeier W et al.. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 2001, 20, 2120-2130.
6. Kawai C. Pathogenesis of acute myocardial infarction. Novel regulatory systems of bioactive substances in the vessel wall. Circulation 1994, 90, 1033-1043.
7. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004, 61, 498-511.
8. Fitzgerald DJ. Platelet activation in the pathogenesis of unstable angina: importance in determining the response to plasminogen activators. Am J Cardiol 1991, 68, 51B-57B.
9. Nieuwenhuis HK, van Oosterhout JJ, Rozemuller E et al. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood 1987, 70, 838-845.
10. Legrand C, Dubernard V, Nurden AT. Studies on the mechanism of expression of secreted fibrinogen on the surface of activated human platelets. Blood 1989, 73, 1226-1234.
11. Johnston GI, Cook RG, McEver RP. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell 1989, 56, 1033-1044.
12. Stenberg PE, McEver RP, Shuman MA et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985, 101, 880-886.
13. Tschoepe D, Spangenberg P, Esser J et al. Flowcytometric detection of surface membrane alterations and concomitant changes in the cytoskeletal actin status of activated platelets. Cytometry 1990, 11, 652-656.
14. Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996, 87, 4925-4936.
15. Abrams CS, Ellison N, Budzynski AZ et al. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990, 75, 128-138.
16. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987, 70, 307-315.
17. Hamm CW, Lorenz RL, Bleifeld W et al. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987, 10, 998-1006.
18. Trip MD, Cats VM, van Capelle FJ et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990, 322, 1549-1554.
19. Michelson AD, Barnard MR, Hechtman HB et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996, 93, 11877-11882.
20. Berger G, Hartwell DW, Wagner DD. P-Selectin and platelet clearance. Blood 1998, 92, 4446-4452.
21. Ault KA, Cannon CP, Mitchell J et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999, 33, 634-639.
22. Becker RC, Tracy RP, Bovill EG et al. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. TIMI-III Thrombosis and Anticoagulation Group. Coron Artery Dis 1994, 5, 339-345.
23. Schultheiss HP, Tschoepe D, Esser J et al. Large platelets continue to circulate in an activated state after myocardial infarction. Eur J Clin Invest 1994, 24, 243-247.
24. Bihour C, Durrieu-Jais C, Besse P et al. Flow cytometry reveals activated GP IIb-IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction. Blood Coagul Fibrinolysis 1995, 6, 395-410.
25. Furman MI, Benoit SE, Barnard MR et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998, 31, 352-358.
26. Michelson AD, Barnard MR, Krueger LA et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001, 104, 1533-1537.
27. Furman MI, Barnard MR, Krueger LA et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001, 38, 1002-1006.
28. Ott I, Neumann FJ, Gawaz M et al. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996, 94, 1239-1246.
29. Gawaz M, Neumann FJ, Ott I et al. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996, 94, 279-285.
30. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994, 331, 489-495.
31. Scharf RE, Tomer A, Marzec UM et al. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb 1992, 12, 1475-1487.
32. Tschoepe D, Schultheiss HP, Kolarov P et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993, 88, 37-42.
33. Neumann FJ, Gawaz M, Ott I et al. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 1996, 27, 15-21.
34. Gawaz M, Neumann FJ, Ott I et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996, 93, 229-237.
35. Kolarov P, Tschoepe D, Nieuwenhuis HK et al. PTCA, periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS). Eur Heart J 1996, 17, 1216-1222.
36. Neumann FJ, Ott I, Gawaz M et al. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 1996, 27, 819-824.
37. Gawaz M, Neumann FJ, Ott I et al. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart 1996, 76, 166-172.
38. Gurbel PA, Bliden KP. Platelet activation after stenting with heparin-coated versus noncoated stents. Am Heart J 2003, 146, E10.
39. Gurbel PA, Callahan KP, Malinin AI et al. Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. J Invasive Cardiol 2002, 14, 584-589.
40. Inoue T, Sohma R, Miyazaki T et al. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol 2000, 86, 1057-1062.
41. Atalar E, Aytemir K, Haznedaroglu I et al. Platelet and leukocyte deactivation after intracoronary stent placement in patients receiving combined antiplatelet therapy. Clin Appl Thromb Hemost 2001, 7, 116-121.
42. Cosemans JM, Kuijpers MJ, Lecut C et al. Contribution of platelet glycoprotein VI to the thrombogenic effect of collagens in fibrous atherosclerotic lesions. Atherosclerosis 2005, 181, 19-27.
43. Penz S, Reininger AJ, Brandl R et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J 2005, 19, 898-909.
44. Cabeza N, Li Z, Schulz C et al. Surface expression of collagen receptor Fc receptor-gamma/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells. Diabetes 2004, 53, 2117-2121.
45. Samaha FF, Hibbard C, Sacks J et al. Density of platelet collagen receptors glycoprotein VI and alpha2beta1 and prior myocardial infarction in human subjects, a pilot study. Med Sci Monit 2005, 11, 224-229.
46. Bigalke B, Lindemann S, Ehlers R et al. Expression of platelet collagen receptor VI is associ-ated with acute coronary syndrome. Eur Heart J 2006, 27, 2165-2169.
47. Oppenheimer, GM. Becoming the Framingham Study 1947-1950. J Public Health 2005, 95, 602-610.
48. .Wilson WF, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97, 1837-1847.
49. .Anderson KM, Wilson PW, Odell PM et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991, 83, 356-362.
50. Davi G, Catalano I, Averna M et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990, 322, 1769-1774.
51. Fitzgerald GA, Oates JA, Nowak J. Cigarette smoking and hemostatic function. Am Heart J 1988, 115, 267-271.
52. Wennmalm A, Benthin G, Grantström EF et al. Maintained hyperexcretion of thromboxane A2 metabolite in healthy young cigarette smokers: results from a prospective study in randomly sampled males with stable smoking habits. Clin Physiol 1993, 13, 257-264.
53. Dotevall A, Rangemark C, Eriksson E et al. Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. Thromb Haemost 1992, 68, 583-588.
54. Saareks V, Riutta A, Mucha I et al. Nicotine and cotinine modulate eicosanoid production in human leucocytes and platelet rich plasma. Eur J Pharmacol 1993, 248, 345-349.
55. Hjemdahl P. Smoking, nicotine and thrombotic risk - a role for platelet dependent thrombin generation? Eur Heart J 2001, 22, 16-18.
56. Davi G, Averna M, Catalano I et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 1992, 85, 1792-1798.
57. Davi G, Gresele P, Violi F et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997, 96, 69-75.
58. Collaborative overview of randomised trials of antiplatelet therapy-I, Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Br Med J 1994, 308, 81-106.
59. Yusuf S, Zhao F, Mehta SR et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345, 494-502.
60. Cuisset T, Frere C, Quilici J et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006, 4, 542-549.
61. Cuisset T, Frere C, Quilici J et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006, 48, 1339-13345.
62. Xiao Z, Theroux P. Clopidogrel inhibits plateletleukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004, 43, 1982-1988.
63. Geisler T, Langer H, Wydymus M et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006, 27, 2420-2425.
64. Hochholzer W, Trenk D, Bestehorn HP et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006, 48, 1742-1750.
65. Wenaweser P, Dorffler-Melly J, Imboden K et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005, 45, 1748-1752.
66. Fitzgerald DJ, Roy L, Catella F et al. Platelet activation in unstable coronary disease. N Engl J Med 1986, 315, 983-989.
67. Schultheiss HP, Tschoepe D, Esser J et al. Large platelets continue to circulate in an activated state after myocardial infarction. Eur J Clin Invest 1994, 243-247.
68. Heeschen C, Dimmeler S, Hamm CW et al. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348, 1104-1111.